Immunome (NASDAQ:IMNM) Sets New 52-Week Low - Here's Why

Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $8.96 and last traded at $8.95, with a volume of 164836 shares traded. The stock had previously closed at $9.35.

Analyst Ratings Changes

IMNM has been the topic of several research reports. Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They issued an "overweight" rating and a $30.00 price objective on the stock. Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Finally, Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Immunome in a research report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has an average rating of "Buy" and an average price target of $28.60.

Immunome Stock Up 5.7 %

The stock has a fifty day moving average price of $10.33 and a two-hundred day moving average price of $12.18. The company has a market cap of $749.90 million, a price-to-earnings ratio of -1.16 and a beta of 1.90.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the firm's stock in a transaction on Friday, January 31st. The shares were purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 8.60% of the stock is owned by insiders.

Remove Ads

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. BNP Paribas Financial Markets acquired a new stake in Immunome during the fourth quarter worth approximately $70,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Immunome during the 4th quarter worth $75,000. AlphaQuest LLC grew its holdings in shares of Immunome by 786,700.0% during the 4th quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock worth $84,000 after purchasing an additional 7,867 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock worth $91,000 after purchasing an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new position in Immunome in the fourth quarter valued at about $95,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.